GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Rating of “Hold” from Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have received an average recommendation of “Hold” from the eighteen ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $8.76.

A number of equities analysts recently weighed in on the stock. Truist Financial boosted their price target on shares of GoodRx from $7.50 to $8.00 and gave the stock a “hold” rating in a research report on Friday, March 1st. Bank of America lowered shares of GoodRx from a “buy” rating to an “underperform” rating and lowered their price target for the stock from $8.00 to $4.50 in a research report on Tuesday, January 2nd. Leerink Partnrs restated an “outperform” rating on shares of GoodRx in a research report on Monday, February 26th. SVB Leerink initiated coverage on shares of GoodRx in a research note on Monday, February 26th. They set an “outperform” rating and a $8.00 target price on the stock. Finally, The Goldman Sachs Group lifted their target price on shares of GoodRx from $6.50 to $7.50 and gave the stock a “neutral” rating in a research note on Friday, March 1st.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Gerber LLC acquired a new position in shares of GoodRx in the 4th quarter valued at $75,000. Syon Capital LLC acquired a new position in shares of GoodRx in the 4th quarter valued at $168,000. Legal & General Group Plc boosted its holdings in shares of GoodRx by 7.9% in the 4th quarter. Legal & General Group Plc now owns 65,755 shares of the company’s stock valued at $441,000 after buying an additional 4,802 shares in the last quarter. Prelude Capital Management LLC boosted its holdings in shares of GoodRx by 20.7% in the 4th quarter. Prelude Capital Management LLC now owns 60,597 shares of the company’s stock valued at $406,000 after buying an additional 10,413 shares in the last quarter. Finally, Rip Road Capital Partners LP boosted its holdings in shares of GoodRx by 25.8% in the 4th quarter. Rip Road Capital Partners LP now owns 1,763,277 shares of the company’s stock valued at $11,814,000 after buying an additional 361,294 shares in the last quarter. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Stock Up 1.3 %

Shares of NASDAQ GDRX opened at $7.10 on Friday. The company’s 50-day simple moving average is $6.75 and its 200-day simple moving average is $6.09. GoodRx has a 52-week low of $4.14 and a 52-week high of $9.37. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of -354.82, a price-to-earnings-growth ratio of 3.87 and a beta of 1.44. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.85.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Thursday, February 29th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. GoodRx had a negative net margin of 1.18% and a positive return on equity of 2.45%. The business had revenue of $196.64 million for the quarter, compared to analyst estimates of $195.59 million. Equities analysts predict that GoodRx will post 0.23 EPS for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.